

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Cannara Biotech Inc. (the "Issuer")

Trading Symbol: LOVE

Number of Outstanding Listed Securities: 709,970,705 common shares

Date: March 3, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Farnham Facility (Indoor Cannabis Cultivation and Processing)

Following the grant of the cannabis cultivation licence by Health Canada, the Company has officially launched its production on February 3, 2020 at the Farnham Facility.

The first cultivation lot (2 flowering rooms) is forecasted to be harvested in the second quarter of calendar year 2020. The Company continues to engage staff and methodologically propagating its remaining flowering rooms.

ShopCBD.com

Given ongoing regulatory uncertainty and marketing restrictions governing the sale of hemp-derived CBD products, the Company is working on reinforcing the strategy to compete in the market.

2. Provide a general overview and discussion of the activities of management.

Management is focused on the successful launch of cultivation activities at the Farnham Facility following the grant of the cultivation licence by Health Canada.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Management had ongoing discussions with strategic partners, but no formal arrangement reached yet.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how

the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company had 15 new hires to support the launch of the cultivation and 1 termination in February 2020.

Report on any labour disputes and resolutions of those disputes if applicable.

N/A

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common shares	3,000,000	Warrants exercised	\$300,000 will be used for current operations
Options	655,000	Options Granted	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

14. Provide details of any loans to or by Related Persons.

No new transactions

15. Provide details of any changes in directors, officers or committee members.

Dr. Sara May, President of FV Pharma Inc. will step down from Company's Board of Directors following the transaction in which Cannara Insiders acquired all of FV Pharma's position in Cannara

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 3, 2020.

Lennie Ryer

Name of Director or Senior
Officer


Signature

Chief Financial Officer
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/D
Cannara Biotech Inc.		January	2020/03/03
Issuer Address			
333 Décarie Boulevard, Suite 200			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Saint-Laurent, Québec, H4N 3M9		()	(514) 543-4200
Contact Name		Contact Position	Contact Telephone No.
Lennie Ryer		CFO	(514) 913-9136
Contact Email Address		Web Site Address	
Lennie@cannara.ca		www.cannara.ca	